PARP Inhibitors in Metastatic Prostate Cancer: Efficacy, Trials, and Combination Therapies ...

PARP Inhibitors in Metastatic Prostate Cancer: Efficacy, Trials, and Combination Therapies ...

The meeting featured international societies and the first Spanish language abstract session, enhancing global collaboration in sexual medicine. Instructional courses covered topics like androgens, ...

Disparities in BPH treatment reimbursement across Canada may affect the adoption of new technologies and influence treatment choices. Current reimbursement models may lead to potential misuse and ...

Lu-PSMA-I&T significantly extended rPFS in PSMA-positive mCRPC patients compared to hormone therapy in the ECLIPSE trial. The trial enrolled over 400 patients globally, with primary and secondary ...

Stone Clear provides a non-invasive option for managing post-lithotripsy kidney stone fragments, reducing complications and repeat procedures. Ultrasonic propulsion significantly extends time to ...

PARP Inhibitors in Metastatic Prostate Cancer: Efficacy, Trials, and Combination Therapies ...

PARP Inhibitors in Metastatic Prostate Cancer: Efficacy, Trials, and Combination Therapies ...

The Evolving Role of Radium-223 in mCRPC and the Impact of Combination Therapies ...

The Evolving Role of Radium-223 in mCRPC and the Impact of Combination Therapies ...

Bone scans have been the standard for staging metastatic prostate cancer due to their ability to detect bone metastases indirectly. PSMA-PET offers superior specificity and accuracy compared to bone ...

Clarity Pharmaceuticals and Nucleus RadioPharma collaborate to develop Cu-SAR-bisPSMA for mCRPC treatment in the SECuRE trial. The SECuRE trial's cohort 4 shows promising safety and efficacy, with no ...